One-fifth of 340B hospitals will garner no repayment from Medicare for past underpayments, according to a recent analysis by a [...] …
Category: Research/Reports
Medicare paid hospitals substantially more—almost $4 billion in aggregate—than the 340B ceiling price costs for dozens of single-source drugs, biologics [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Prescribers who work in federally qualified health centers (FQHCs) believe the 340B program helps their organizations and patients—even if they [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A recent analysis of the increasing annual total number of drug manufacturer refunds to 340B covered entities notes they are [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Active 340B contract pharmacies reached 17,250 in 2024, according to a conservative think tank using data collected by another group funded by [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Eighty-five percent of DSH hospitals earned more in estimated 340B revenue in 2022 than they incurred in charity care costs, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Significant gaps in hospital and health system’s financial data, including 340B program use, “limit transparency for policymakers, researchers, and consumers,” [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
An influential conservative congressional caucus is urging Congress to significantly cut Medicaid spending and “ to ensure that drug discounts [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The 340B program may increase medication costs for self-insured employers, a recent study from a pharmaceutical industry outsourcing and analytics [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Although 340B participation did not correlate to the start of costly treatment for men with advanced prostate cancer enrolled in [...] …
